SCHEMBL6940880

SCHEMBL6940880

O=c1[c]cc2cc(S(=O)(=O)Nc3ccccc3)c(Cl)cc2n1P(=O)(O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
WDR5 P61964 2/20 0.42
PGR P06401 1/20 0.40
ITGA1 P56199 2/20 0.38
LMNA P02545 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
GPR27 Q9NS67 2/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
BRD4 O60885 1/20 0.36
BRD1 O95696 1/20 0.36
BRPF1 P55201 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6940575 0.83 KAT6A (0.43) MEN1KMT2AALDH1A1
SCHEMBL6939753 0.83 KMT2A (0.34) PIK3CDPIK3CAPIK3CBPIK3CGKMT2A
SCHEMBL7650678 0.83 ALDH1A1 (0.40) LMNAKDM4EHTTMAPK1ALDH1A1
SCHEMBL7652661 0.80 GSTO1 (0.37) MAPTLMNAKDM4EALDH1A1
SCHEMBL7648790 0.80 POLB (0.30)
SCHEMBL7652258 0.76 ALDH1A1 (0.43) MAPTBRD4MEN1KMT2AMAPK1
SCHEMBL7651550 0.76 GAA (0.40) MEN1KMT2AKDM4EALDH1A1
Bromide SCHEMBL6937197 0.75 GAA (0.39) MEN1KMT2AKDM4EALDH1A1
SCHEMBL6937183 0.72 PGR (0.48) MAPTWDR5PGRITGA1EGLN1
SCHEMBL7650719 0.70 CA9 (0.44) MAPTMEN1KMT2AKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1125942-B1 Derivatives of 6-amino or 6-hydrazinosulfonyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-04-09 EP claimed
US-6486143-B2 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS LES LABORATOIRES SERVIER (FR) 2002-11-26 US claimed
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2001-10-18 US claimed
US-6486143-B2 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS LES LABORATOIRES SERVIER (FR) 2002-11-26 US disclosed
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds CA6, P2RY6, FPR3 MAPT 4631/4885WDR5 3966/4885PGR 4195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.